Attenuated respiratory syncytial virus vaccine compositions

Details Attenuated respiratory syncytial virus vaccine compositions Attenuated respiratory syncytial virus vaccine compositions

1994-10-21

1999-07-13

Caputa, Anthony C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4352351, 435236, 435237, 435239, A61K 39155, C12N 704, C12N 708

Patent

active

059223260

ABSTRACT:
The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.

REFERENCES:
patent: 4800078 (1989-01-01), Prince et al.
patent: 4866034 (1989-09-01), Ribi
patent: 5250298 (1993-10-01), Gelb
Kim et al. Pediatrics 48(5):745-755, Nov. 1971.
Maasaab et al. Vaccine 3:355-369, Dec. 1985.
Lazar et al. Molecular and Cellular Biology 8(3):1247-1252, Mar. 1988.
Burgees et al. Journal of Cell Biology 111:2129-2138, Nov. 1990.
Friedewold et al., JAMA 204(8):142-146, 1968.
Wright et al., Infection and Immunity 37(1):397-400, 1982.
Edwards et al., Journal of Infectious Diseases 163:740-45, 1991.
Gharpure et al., "Temperature--Sensitive Mutants of Respiratory Syncytial Virus," J. Virol., 3:414-421 (1969).
Hodes et al., "Genetic Alteration in a Temperature Sensitive Mutant of Respiratory Syncytial Virus after Replication in vivo," Proc. Soc. Exp. Biol. Med., 145:1158-1164 (1974).
McIntosh et al., "Attenuated Respiratory Syncytial Virus Vaccines in Asthmatic Children," Pediatr. Res., 8:689-696 (1974).
Belshe et al., "Evaluation of five Temperature--Sensitive Mutants of Respiratory Syncytial Virus in Primates: II. Genetic Analysis of Virus Recovered During Infection," J. Med. Virol., 3:101-110 (1978).
Richardson et al., "Evaluation of Five Temperature--Sensitive Mutants of Respiratory Syncytial Virus in Primates: I. Viral Shedding, Immunologic Response and Associated Illness," J. Med. Virol., 3:91-100 (1978).
Prince et al., "Respiratory Syncytial Virus Infection in Owl Monkeys: Viral Shedding, Immunological Response, and Associated Illness Caused by Wild-Type Virus and Two Temperature--Sensitive Mutants," Infect. Immu., 26:1009-1013 (1979).
Murphy et al., "Production and Level of Genetic Stability of an Influenza A Virus Temperature--Sensitive Mutant Containing Two Genes with ts Mutations," Infect. Immun., 37:235-242 (1982).
Olmsted et al., "Expression of the F Glycoprotein of Respiratory Syncytial Virus by a Recombinant Vaccinia Virus: Comparison of the Individual Contributions of the F and G Glycoproteins to Host Immunity," Proc. Natl. Acad. Sci., 83:7462-7466 (1986).
Walsh et al., "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection," J. Infect. Dis., 155:1198-1204 (1987).
Clements et al., "Evaluation of Bovine, Cold-Adapted Human, and Wild-Type Human Parainfluenza Type 3 Viruses in Adult Volunteers and in Chimpanzees," J. Clin. Microbiol., 29:1175-1182 (1991).
Murphy et al., "Enhanced Pulmonary Histopathology is Observed in Cotton Rats Immunized with Formalin--Inactived Respiratory Syncytial Virus (RSV) or Purified F Glycoprotein and Challenged with RSV 3-6 Months after Immunization," Vaccine, 8:497-502 (1990).
Collins et al., "Evaluation in Chimpanzees of Vaccinia Virus Recombinants that Express the Surface Glycoproteins of Human Respiratory Syncytial Virus," Vaccine, 8:164-168 (1990).
Crowe et al., "A Comparison in Chimpanzees of the Immunogenicity and Efficacy of Live Attenuated Respiratory Syncytial Virus (RSV) Temperature--Sensitive Mutant Vaccines and Vaccinia Virus Recombinants that Express the Surface Glycoproteins of RSV," Vaccine, 11:1395-1404 (1993).
Pringle et al., "Immunogenicity and Pathogenicity of a Triple Temperature--Sensitive Modified Respiratory Syncytial Virus in Adult Volunteers," Vaccine, 11:473-478 (1993).

Affiliated with

Also associated with

Rating

Attenuated respiratory syncytial virus vaccine compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuated respiratory syncytial virus vaccine compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated respiratory syncytial virus vaccine compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2273464